Understanding regenerative medicine: A commissioners viewpoint

Regenerative Medicine

Volumn 8, Issue 2, 2013, Pages 227-232

  Warren, Virginia ^a  

^a BUPA Group Medical Team   (United Kingdom)

Author keywords

algorithms; economics, medical; regenerative medicine; technology assessment, biomedical methods; treatment outcome

Indexed keywords

ANTIVIRUS AGENT; CHONDROCYTE IMPLANT; CYTOVIR; UNCLASSIFIED DRUG;

ALGORITHM; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER RADIOTHERAPY; CELL THERAPY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; FUNDING; GENE THERAPY; HEALTH CARE ACCESS; HEALTH CARE NEED; HEALTH CARE QUALITY; HEALTH ECONOMICS; HUMAN; MASTECTOMY; MORBIDITY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TREATMENT OUTCOME;

BIOMEDICAL TECHNOLOGY; HEALTH PERSONNEL; HUMANS; REGENERATIVE MEDICINE; TISSUE THERAPY;

EID: 84874858134     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.13.5     Document Type: Review

References (30)

1. Warren V. Health technology appraisal of interventional procedures: comparison of rapid and slow methods. J. Health Serv. Res. Policy 12, 142-146 (2007).
2. Horton R. Offline: the scandal of device regulation in the UK. Lancet 379, 204 (2012).
3. Saris DB, Vanlauwe J, Victor J et al. Characterized chondrocyte implantation results in better structural repair when treating symptomatic cartilage defects of the knee in a randomized controlled trial versus microfracture. Am. J. Sports Med. 36(2), 235-246 (2009).
4. Gerlier L, Lamotte M, Wille M et al. The cost utility of autologous chondrocytes implantation using ChondroCelect® in symptomatic knee cartilage lesions in Belgium. Pharmacoeconomics 28, 1129-1146 (2010).
5. Vanlauwe J, Saris DB, Victor J et al. Five-year outcome of characterized chondrocyte implantation versus microfracture for symptomatic cartilage defects of the knee: early treatment matters. Am. J. Sports Med. 39, 2566-2574 (2011).
6. Hill-Kayser CE, Vachani C, Hampshire MK, Di Lullo GA, Metz JM. Cosmetic outcomes and complications reported by patients having undergone breast-conserving treatment. Int. J. Radiat. Oncol. 83, 839-844 (2012).
7. Pérez-Cano R, Vranckx JJ, Lasso JM et al. Prospective trial of adipose-derived regenerative cell (ADRC)-enriched fat grafting for partial mastectomy defects: the RESTORE-2 trial. Eur. J. Surg. Oncol. 38, 382-389 (2012).
8. Redaelli A, Romano D, Marcianó A. Face and neck revitalization with platelet-rich plasma (PRP): clinical outcome in a series of 23 consecutively treated patients. J. Drugs Dermatol. 9, 466-472 (2010).
9. Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. www.clinicaltrials.gov/ct2/show/ NCT00919958?term=PLX-PAD&rank=1 (Accessed 24 August 2012)
10. Debra: Update on EB research progress. www.debra.org.uk/update-on-eb- research-progress.html (Accessed 28 August 2012)
11. Regenerative Medicine. www.parliament.uk/business/committees/ committees-a-z/lords-select/science-and-technology-committee/inquiries/ parliament-2010/regenerative-medicine (Accessed 24 August 2012)
12. SBU evaluates health care technologies. www.sbu.se/en/Published/Post. aspx?epslanguage=EN (Accessed 24 August 2012)
13. Vaccines, Blood and Biologics. www.fda.gov/BiologicsBloodVaccines/ CellularGeneTherapyProducts/ ApprovedProducts/ucm134025.htm (Accessed 24 August 2012)
14. NHS: Published interventional procedures. www.nice.org.uk/Guidance/IP/ Published (Accessed 24 August 2012)
15. NHS: Published technology appraisals. www.nice.org.uk/guidance/ta/ published/ index.jsp?p=off (Accessed 24 August 2012)
16. NHS: Published medical technologies guidance. http://guidance.nice.org. uk/MT/Published (Accessed 24 August 2012)
17. NICE: Medical technologies guidance in development. www.nice.org.uk/ guidance/mt/ indevelopment/index.jsp (Accessed 24 August 2012)
18. Slow-healing Wounds in the Elderly. www.sbu.se/en/Ongoing-projects/Slow- healing-Wounds-in-the-Elderly (Accessed 24 August 2012)
19. Matrix-induced Autologous Chondrocyte Implantation (MACI) and Autologous Chondrocyte Implantation (ACI). www.msac.gov.au/internet/msac/publishing. nsf/Content/app1140-1 (Accessed 24 August 2012)
20. Canadian Agency for Drugs and Technologies in Health. www.cadth.ca/en/search?q=Graftjacket (Accessed 28 August 2012)
21. ChondroCelect®: characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins. www.emea.europa.eu/ema/ index. jsp?curl=pages/medicines/human/ medicines/000878/human-med-000698. jsp&mid=WC0b01ac058001d124 (Accessed 24 August 2012)
22. Regulation (EC) No 1394/2007 On Advanced Therapy Medicinal Products ('The ATMP Regulation'). www.mhra.gov.uk/home/groups/es-policy/ documents/ publication/con051875.pdf (Accessed 19 December 2012)
23. Regenerative Medicine: Official Group. https://connect.innovateuk.org/ web/136128/ document-library?p-p-id=20&p-p- lifecycle=0&p-p-state= normal&p-p- mode=view&p-p-col-id=column-1&p-p- col-count=1&ns- 20-struts-action=%2Fdocument-library%2Fview&ns-20-folderId=7558210 (Note: Registration required) (Accessed 24 August 2012)
24. PubMed search (nil return). www.ncbi.nlm.nih.gov/ pubmed?term= %28%22Technology%20 Assessment,%20Biomedical/ methods%22[Mesh] %29%20AND%20%22Regenerative%20Medicine%22[Mesh] (Accessed 27 August 2012)
25. The Royal College of Pathologists: Publications. www.rcpath.org/ publications-media/ publications/publications.htm Scroll to 'General Documents' and then to July 2006 (Accessed 24 August 2012)
26. ClinicalTrials.gov: Learn About Clinical Studies. http://clinicaltrials. gov/ct2/info/ understand#Q08 (Accessed 24 August 2012)
27. Alternate Donor Study of Pre-Emptive Cellular Therapy (CMV-ACE/ASPECT). www.clinicaltrials.gov/ct2/show/NCT01220 895?term=%22Cell+Medica%22&rank=2 (Accessed 27 August 2012)
28. Cytomegalovirus -Immunoprophylactic Adoptive Cellular Therapy Study (CMV IMPACT). www.clinicaltrials.gov/ct2/show/NCT01077 908?term= Cell+Medica&cntry1=EU%3AG B&rank=1 (Accessed 27 August 2012)
29. Pilot Investigation of Stem Cells in Stroke (PISCES). www.clinicaltrials.gov/ct2/show/NCT011511 24?term=ReNeuron&rank=1 (Accessed 27 August 2012)
30. The Project. www.thelondonproject.org/OurVision/ TheProject/?id=76 (Accessed 27 August 2012)